Navigation Links
Researchers from the University of Navarra analyze new kinds of cancer-fighting antibodies

Two researchers from the University Hospital and the Center for Applied Medical Research (CIMA) from the University of Navarra have published an article in Nature Cancer Reviews, one of the leading scientific journals in the area of cancer studies. The article, written by Ignacio Melero and Sandra Hervas-Stubbs, together with other scientists from the United States and Great Britain, addresses the use of a new pharmaceutical family with practical applications in cancer and chronic viral illnesses.

Specifically, the article discusses using monoclonal antibodies in order to stimulate the immune system. In this therapy the antibodies are directed to the immune system cells in order to provoke a stronger reaction against cancer. This has the advantage of exploiting a mechanism with an action distinct from the other strategies currently being used to treat cancer, and is capable of interacting with the current treatments so as to make both forms of treatment more powerful.

Currently this treatment is being tested in patients with melanoma, kidney and ovarian cancer because there are more ways of measuring the response of the immune system, but he expects to be able to expand this to include other forms of cancer.

Five cancer-fighting agents being tested

The first cancer-fighting agent of this kind, anti-CTLA-4, began to be tested in patients in 1999. In melanoma treatment, between 15 and 20% of clinical objectives have been reached (reduction or disappearance of the tumor), which the researchers see as a positive sign to continue with the research.

Currently, the researchers study its benefits in cancer survivors through two clinical tests in the third phase. In two years we will test its use as the sole means of treatment, and we will need more time in order to know if its effects in treatment combinations are as positive as the results on test animals predict.

Aside from this, there are another f
'"/>

Source:Elhuyar Fundazioa


Page: 1 2

Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. Researchers reveal the infectious impact of salmon farms on wild salmon
5. Researchers identify target for cancer drugs
6. Researchers discover molecule that causes secondary stroke
7. Researchers find missing genes of ancient organism
8. Researchers trace evolution to relatively simple genetic changes
9. Researchers add new tool to tumor-treatment arsenal
10. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
11. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain

Post Your Comments:
(Date:11/9/2009)...-- Genencor, a division of Danisco, has won the na...n Institute of Chemical Engineers (AIChE) for its ... ethanol. Yesterday, Robert Davis, Chair of the AI...n Steele, who is Marketing Director, Biomass Enzym...n Kelley, who is Senior Engineer, Biomass Applicat...
(Date:11/8/2009)...rdue University have discovered a new approach for...uries using nano-spheres that could be injected in...nthetic "copolymer micelles" are drug-delivery sph...00 times smaller than the diameter of a red blood ...liver drugs for cancer treatment and other therapi...
(Date:11/6/2009)...y with their arboreal hosts. But new research sugg...s of choice, the ants can get destructive to neigh...ovember issue of the American Naturalist , is the... and it reopens a centuries-old debate on the rela...tain species of plants and trees have cozy relatio...
Breaking Biology News(10 mins):Genencor Wins The American Institute of Chemical Engineers (AIChE) Sustainable Energy Award For Accellerase(R) Cellulosic Ethanol Enzymes 2Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Ants are friendly to some trees, but not others 2Biomimetic engineering design can replace spaghetti tangle of nanotubes in novel material 12400 1Biomimetic engineering design can replace spaghetti tangle of nanotubes in novel material 12400 2Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions 4509 1Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions 4509 2Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions 4509 3Streamwood Hospital Opens New Childrens Center to Meet Vital Community Need 47557 1Streamwood Hospital Opens New Childrens Center to Meet Vital Community Need 47557 2
...The legacy of nuclear weapons and nuclear energy d...ozens of sites across the United States and many m...e uranium is transported through ground water as u...um immobilization in contaminated ground water and...ic molecules known as electron donors to stimulate...
...in the UK and funded by the UK Biotechnology and B... a new drug discovery tool to identify a new playe...nding could spark a completely new class of drugs ...is week in Nature Chemical Biology researchers a...askatchewan graduate Dr Grant Churchill, explain h...
...ed an algorithm that meshes existing data to produ...respond to stimuli. Using this new method, Whitehe...logy scientists have analyzed alpha-synuclein toxi...t cell survival. Misfolded copies of the alpha-syn...rkinson,s disease. , RELEVANCE: Until now, data o...
Other Biology News:Patience pays off with methanol for uranium bioremediation 2Canadian scientist mines drugs database for new diabetes treatment 2Calculating gene and protein connections in a Parkinson's disease model 2Calculating gene and protein connections in a Parkinson's disease model 3Calculating gene and protein connections in a Parkinson's disease model 4
(Date:11/9/2009)..., SAN DIEGO, Nov. 9 BioM...y that the company has received commitments from l...nsecured line of credit by $65 million to an aggre... terms of the facility. The weighted-average effe...t was 1.35% as of September 30, 2009. The maturity...
(Date:11/9/2009)..., SAN DIEGO, Nov. 9 NexBio, Inc. a...annual American College of Allergy, Asthma, and Im...entitled "DAS181 (Fludase®), a Sialidase, Dec...mmatory Effects in Animal Models of Asthma". ,,...oad spectrum host-targeting drug candidate being s...
(Date:11/9/2009)... Product release is a researc...jects, research facilities and research safety stu... , Cedar Knolls, NJ (PRWE...unced today that it has unveiled Pristima™ V...research facilities that track the use and care of...
(Date:11/8/2009)..., MOUNTAIN VIEW, Calif. Nov. 5, 2009 Complete...ing company, today announced publication of a repo...tary DNA sequencing platform, including analysis o... The consumables cost for these three genomes sequ...rays ranged from $8,005 for 87x coverage to $1,726...
Breaking Biology Technology:BioMed Realty Trust Receives Commitments to Expand Unsecured Line of Credit to $665 Million 2BioMed Realty Trust Receives Commitments to Expand Unsecured Line of Credit to $665 Million 3NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 2NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 3Xybion Unveils Pristima™ VM, an Integrated Enterprise Software Solution for Vivarium and Veterinary Care Management 2Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes 2
... Biotech Products, L. P. Supports Program to Recog...o recognize the,extraordinary commitment of oncolo...ounced its support of CURE magazine,s 2008 Extraor...nors one of the thousands of,exceptional oncology ...cation, compassion and helpfulness. Last year, mor...
...ands the Company,s Clinical Stage Product Portfoli...uticals,Inc. today announced that it is has comple...and commercialize products under AstraZeneca,s IP ...tors (AI) in combination with,estrogen and progest...Meditrina,s clinical stage product portfolio which...
...ERSBURG, Md., Feb. 6 Iomai Corporation,(Nasdaq: ...ompany,s,president and chief executive officer, wi...onference in New York City on Tuesday, Feb. 12. Mr... Time in the in New Amsterdam,Suite of the Waldorf...ate and clinical milestones and,detail the results...
Other Biology Technology:Call for Entries - 2008 CURE Extraordinary Healer Award for Oncology Nursing 2Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca 2Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca 3Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12 2
Mouse Anti-20S Proteasome alpha1, 2, 3, 5, 6, & 7-Subunits Monoclonal Antibody, Unconjugated, Clone MCP231 from Calbiochem
...een the 500 l and 4 ml centrifugal concentrators. ...spin products with low internal surface and membra...olutions. ,Available with a choice of PES, Cell...highest flexibility for process optimisation. ,A...
Mouse Anti-HSV-2 Glycoprotein G-2 Monoclonal Antibody, Unconjugated, Clone H1206 from Meridian Life Science, Inc.
...Region By immunoblotting the antibody reacts again...free MMP-2 or MMP-2 bound to TIMP-2. affinity isol... Solution in 0.01 M phosphate buffered saline, pH ...e. synthetic peptide corresponding to the hinge re...
Biology Products: